NASDAQ:XNCR Xencor (XNCR) Stock Price, News & Analysis $19.11 -1.15 (-5.68%) As of 01/14/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Xencor Stock (NASDAQ:XNCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xencor alerts:Sign Up Key Stats Today's Range$19.05▼$20.5050-Day Range$19.11▼$26.8452-Week Range$15.31▼$27.24Volume563,155 shsAverage Volume539,944 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice Target$36.56Consensus RatingBuy Company OverviewXencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.Read More… Xencor Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks86th Percentile Overall ScoreXNCR MarketRank™: Xencor scored higher than 86% of companies evaluated by MarketBeat, and ranked 173rd out of 955 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingXencor has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXencor has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Xencor's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Xencor are expected to grow in the coming year, from ($3.71) to ($3.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.13% of the outstanding shares of Xencor have been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Xencor has recently increased by 21.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.24 Percentage of Shares Shorted7.13% of the outstanding shares of Xencor have been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Xencor has recently increased by 21.41%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.07 News SentimentXencor has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Xencor this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Xencor to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,277,609.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Xencor is held by insiders.Read more about Xencor's insider trading history. Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address XNCR Stock News HeadlinesBank of America Securities Remains a Buy on Xencor (XNCR)January 14 at 11:17 PM | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Xencor (XNCR) and Pfizer (PFE)January 14 at 6:17 PM | markets.businessinsider.comLooking for ways to bring in extra cash? These days folks are constantly looking for ways to bring in extra cash… Picking up extra hours, working weekends, and even getting second or third jobs! But what if there was a way to have a “side hustle” that doesn't require you picking up extra shifts or sacrificing your weekends? That my friends, is the beauty of the Weekend Side Hustle!January 15, 2025 | DTI (Ad)Xencor, Inc. (NASDAQ:XNCR) Receives $36.56 Consensus Target Price from BrokeragesJanuary 12 at 3:11 AM | americanbankingnews.comXencor initiated with an Overweight at Wells FargoDecember 13, 2024 | markets.businessinsider.comXencor’s Promising Pipeline and Strategic Partnerships Drive Buy RatingDecember 13, 2024 | markets.businessinsider.comWells Fargo Initiates Coverage of Xencor (XNCR) with Overweight RecommendationDecember 13, 2024 | msn.comPromising Prospects for Xencor’s Plamotamab in Autoimmune Treatments Drive Buy RatingDecember 11, 2024 | markets.businessinsider.comSee More Headlines XNCR Stock Analysis - Frequently Asked Questions How have XNCR shares performed this year? Xencor's stock was trading at $22.98 at the start of the year. Since then, XNCR stock has decreased by 16.8% and is now trading at $19.11. View the best growth stocks for 2025 here. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.27. The business's revenue was down 81.9% compared to the same quarter last year. Who are Xencor's major shareholders? Top institutional shareholders of Xencor include GAMMA Investing LLC. Insiders that own company stock include Bassil I Dahiyat, John R Desjarlais, John J Kuch, Allen Yang, Celia Eckert, Alan Bruce Montgomery and Kurt A Gustafson. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xencor investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings11/06/2024Today1/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XNCR CUSIPN/A CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees280Year FoundedN/APrice Target and Rating Average Stock Price Target$36.56 High Stock Price Target$50.00 Low Stock Price Target$28.00 Potential Upside/Downside+91.3%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,090,000.00 Net Margins-232.77% Pretax Margin-229.85% Return on Equity-30.92% Return on Assets-21.74% Debt Debt-to-Equity Ratio0.01 Current Ratio6.23 Quick Ratio6.23 Sales & Book Value Annual Sales$85.16 million Price / Sales15.70 Cash FlowN/A Price / Cash FlowN/A Book Value$10.99 per share Price / Book1.74Miscellaneous Outstanding Shares69,982,000Free Float66,322,000Market Cap$1.34 billion OptionableOptionable Beta0.72 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:XNCR) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.